CXCL1 and systemic sclerosis: There were also correlations between ΔCXCL1 and ΔSP-A, between CXCL1 levels after rituximab and %FVC after rituximab, and between CXCL1 levels after rituximab and SP-D levels after rituximab, suggesting that serum CXCL1 levels are involved in SSc-ILD progression, and there are B-cell-related mechanisms there.